Gamco Investors INC. ET AL maintained its position in shares of Laboratory Corporation of America Holdings (NYSE:LH) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,400 shares of the medical research company’s stock at the end of the second quarter. Gamco Investors INC. ET AL’s holdings in Laboratory Corporation of America Holdings were worth $524,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Parallel Advisors LLC raised its stake in Laboratory Corporation of America Holdings by 377.7% in the first quarter. Parallel Advisors LLC now owns 1,261 shares of the medical research company’s stock worth $177,000 after buying an additional 997 shares during the period. IFP Advisors Inc raised its stake in Laboratory Corporation of America Holdings by 83.9% in the second quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock worth $177,000 after buying an additional 523 shares during the period. Ingalls & Snyder LLC bought a new stake in Laboratory Corporation of America Holdings during the first quarter worth $206,000. Oppenheimer Asset Management Inc. bought a new stake in Laboratory Corporation of America Holdings during the first quarter worth $208,000. Finally, TNB Financial bought a new stake in Laboratory Corporation of America Holdings during the second quarter worth $208,000. Institutional investors and hedge funds own 93.19% of the company’s stock.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 153.84 on Thursday. The company has a 50-day moving average price of $156.06 and a 200-day moving average price of $145.76. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The stock has a market cap of $15.66 billion, a price-to-earnings ratio of 21.55 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.07. The firm had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. Laboratory Corporation of America Holdings’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business posted $2.36 earnings per share. Equities analysts anticipate that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/31/gamco-investors-inc-et-al-continues-to-hold-stake-in-laboratory-corporation-of-america-holdings-lh.html.

A number of research firms have recently weighed in on LH. Barclays PLC increased their price objective on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. BidaskClub lowered Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Zacks Investment Research raised Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Credit Suisse Group lowered Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 price objective for the company. in a research note on Thursday, July 13th. They noted that the move was a valuation call. Finally, Craig Hallum reissued a “buy” rating and set a $179.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $159.75.

In related news, insider Lisa J. Uthgenannt sold 5,000 shares of Laboratory Corporation of America Holdings stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total value of $800,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider F Samuel Eberts III sold 31,500 shares of Laboratory Corporation of America Holdings stock in a transaction on Friday, August 25th. The shares were sold at an average price of $155.22, for a total value of $4,889,430.00. Following the completion of the transaction, the insider now owns 31,894 shares of the company’s stock, valued at $4,950,586.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,568 shares of company stock valued at $7,127,415. 0.90% of the stock is currently owned by company insiders.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.